Takehiro Hayashi
Kanazawa, 9208641, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Beta-Hydroxyisovaleryl-Shikonin Eradicates Epithelial Cell Adhesion Molecule-Positive Liver Cancer Stem Cells by Suppressing dUTP Pyrophosphatase Expression.
Journal: International journal of molecular sciences
Published: October 16, 2023
Plasma Antithrombin III Levels Can Be a Prognostic Factor in Liver Cirrhosis Patients with Portal Vein Thrombosis.
Journal: International journal of molecular sciences
Published: January 28, 2023
Investigation of Thrombosis Volume, Anticoagulants, and Recurrence Factors in Portal Vein Thrombosis with Cirrhosis.
Journal: Life (Basel, Switzerland)
Published: July 21, 2020
Inactivation of Transcriptional Repressor Capicua Confers Sorafenib Resistance in Human Hepatocellular Carcinoma.
Journal: Cellular and molecular gastroenterology and hepatology
Published: June 07, 2019
Danaparoid sodium-based anticoagulation therapy for portal vein thrombosis in cirrhosis patients.
Journal: BMC gastroenterology
Published: January 22, 2019
Establishment and Characterization of a New Cell Line Permissive for Hepatitis C Virus Infection.
Journal: Scientific reports
Published: June 12, 2018
A Novel mTOR Inhibitor; Anthracimycin for the Treatment of Human Hepatocellular Carcinoma.
Journal: Anticancer research
Published: April 27, 2017
Sporadic PCDH18 somatic mutations in EpCAM-positive hepatocellular carcinoma.
Journal: Cancer cell international
Published: February 28, 2017
Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study.
Journal: BMC cancer
Published: December 19, 2016
Sorafenib suppresses extrahepatic metastasis de novo in hepatocellular carcinoma through inhibition of mesenchymal cancer stem cells characterized by the expression of CD90.
Journal: Scientific reports
Published: December 16, 2016
De Novo Emergence of Mesenchymal Stem-Like CD105+ Cancer Cells by Cytotoxic Agents in Human Hepatocellular Carcinoma.
Journal: Translational oncology
Published: December 01, 2016
TSU-68 ameliorates hepatocellular carcinoma growth by inhibiting microenvironmental platelet-derived growth factor signaling.
Journal: Anticancer research
Published: March 10, 2015
Last Updated: 09/26/2026